CRIS (Curis Corp) Forward P/E Multiple

Official company branding of Curis (CRIS)

Curis, Inc. strictly adheres to environmental regulations by implementing energy saving and emission filtration in its laboratories. The expected P/E trend for Curis, Inc. on the GURU.Markets chart demonstrates investor demand, while the 0.00 metric confirms the current level. The business relies on scaling precision oncology and emavusertib, while stable management develops partnerships with pharma behemoths for the therapy of hematological diseases.

curis.com - CRIS Forward P/E Multiple (period 07/04/2022 - 11/15/2026)
Brand item of Curis Corp

This indicator reflects the ratio of current share price to projected earnings, allowing for the mitigation of time lags between financial reports. Analyzing the forward P/E for the next year of Curis, Inc. (CRIS) helps investors assess the fairness of the market price, which is critical for Curis, Inc. (CRIS), as its impeccable reputation in leukemia therapy development lays the foundation for long-term capitalization growth.

Analysis of competing companies

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|CEL-SCI - Forward P/E Multiple|OSTX - Forward P/E Multiple|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|ARTV - Market Cap to Projected Earnings|Projected Price to Earnings ANL|Future Price to Earnings VERU|Forward P/E Multiple TPST|XLO: Price to Expected Earnings Ratio|Forward P/E Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Projected Price to Earnings Ratio|Kairos Pharma Ltd - Forward P/E Multiple|Price to Expected Earnings Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Future Price to Earnings|Projected Price to Earnings Apollomics, Inc.|Projected Price to Earnings THAR|Price to Future Earnings Ratio ADVB (Advanced Biomed)|Projected Price to Earnings GNPX (Genprex, Inc)|CLDI: Price to Expected Earnings Ratio|Future Price to Earnings sunshinebiopharma.com SBFM|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple